Jean M. Francis, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Nephrology

MD, Lebanese University




Research Interests:

1- Thrombotic microangiopathy (TMA) is a rare but very serious condition. It is characterized by widespread microthrombi formation in multiple organs (in its severe and disseminated form) or localized microthrombi in the kidney (in its limited form). TMA is usually characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and multiple organ injury and dysfunction.

Early detection and accurate diagnosis are essential to implement appropriate therapies, and improve patients’ prognosis and survival. Delay in diagnosis could result in late implementation of appropriate therapies, and this could result in permanent and irreversible organ damage. Left untreated TMA is associated with very high level of morbidity and mortality. TMA presentation could be highly variable making the diagnosis even more difficult. Once the diagnosis of TMA is established, defining the underlying cause is even more challenging due to frequent overlap between the common causes of TMA.

We have a unique multidisciplinary approach to the management of this very rare disease. A TMA team was established at Boston University Medical Center with the primary objective of improving patients care and outcome. Our Team works in close collaboration with the ARC on Thrombosis.

A primary goal of the team is to provide excellent patient care. The TMA team is multidisciplinary involving: nephrologists, hematologists, the director of apheresis, pediatric hematologist and pharmacist. They are always available to manage any patient with suspected TMA. Special protocols and algorithm have been created by the team to help guiding the provider in making an accurate diagnosis of any TMA case.

Another goal of the TMA team is educational. We are actively spreading awareness of this rare disease between our providers at BMC, and also regionally and nationally by organizing lectures and seminars as well as mini-symposia.

A third goal of the TMA team is to advance basic and clinical research related to TMA. We are active in clinical trials addressing the efficacy of newer agents for the treatment of complement mediated HUS a special form of TMA. Our scientists are also trying to understand some underlying pathological mechanisms that could be contributing to TMA.

2- As the Medical Director of the Kidney Transplant program at BUSM and BMC, I am involved in all aspect of care related to kidney transplantation. We evaluate kidney transplant recipients and donors, and manage all the care of post transplant patients. My interests include, BK virus infection, Antibody Mediated Rejection, recurrent GN after kidney transplantation, and metabolic disorders after kidney transplantation.

3- I am the Medical Director of the combined Pancreas Transplant Program between BUMC and BWH. This is a combined program between the two institutions that facilitate the cure of type 1 & 2 DM with pancreas transplantation in very selected patients.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research



2018-2019 Boston University School of Medicine: Faculty Induction into Alpha Omega Alpha Society
2016-2017 Boston University School of Medicine: Excellence In Teaching Award, Hospital Based Faculty
2016-2017 Boston University School of Medicine : Nominated for Clinical Innovation Award
2015-2016 Boston University School of Medicine: Excellence In Teaching Award, Hospital Based Faculty
2014-2015 Boston University School of Medicine: Excellence in Teaching Award, Subspeciality Faculty



Atypic Hemolytic Uremic Syndrome (aHUS)
03/17/2017 - 03/17/2019 (PI)
Alexion Pharmaceuticals


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Angel-Korman A, Stern L, Angel Y, Sarosiek S, Menn-Josephy H, Francis J, Ghai S, Sloan JM, Sanchorawala V, Havasi A. The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2020 Apr; 5(4):485-493.View Related Profiles. PMID: 32274452
     
  2. Addo-Tabiri NO, Chudasama R, Vasudeva R, Leiva O, Garcia B, Ravid JD, Bunze T, Rosen L, Belghasem M, Francis J, Brophy M, Johnson B, Ferguson R, Weinberg J, Chitalia VC. Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism. Am J Clin Oncol. 2020 02; 43(2):94-100.View Related Profiles. PMID: 31809329
     
  3. Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, Belghasem M, Vellard I, Yin W, Ravid JD, Zavaro E, Amraei R, Francis J, Phatak U, Rifkin IR, Rahimi N, Chitalia VC. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019 12 27; 9(1):20257.View Related Profiles. PMID: 31882749
     
  4. Belghasem M, Roth D, Richards S, Napolene MA, Walker J, Yin W, Arinze N, Lyle C, Spencer C, Francis JM, Thompson C, Andry C, Whelan SA, Lee N, Ravid K, Chitalia VC. Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis. Blood. 2019 12 26; 134(26):2399-2413.View Related Profiles. PMID: 31877217
     
  5. Walker JA, Richards S, Belghasem ME, Arinze N, Yoo SB, Tashjian JY, Whelan SA, Lee N, Kolachalama VB, Francis J, Ravid K, Sherr D, Chitalia VC. Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease. Kidney Int. 2020 03; 97(3):538-550.View Related Profiles. PMID: 31932072
     
  6. Belghasem ME, A'amar O, Roth D, Walker J, Arinze N, Richards SM, Francis JM, Salant DJ, Chitalia VC, Bigio IJ. Towards minimally-invasive, quantitative assessment of chronic kidney disease using optical spectroscopy. Sci Rep. 2019 05 09; 9(1):7168.View Related Profiles. PMID: 31073168
     
  7. Singh P, Chen H, Gordon CE, Ghai S, Sloan JM, Quillen K, Moradi S, Chitalia V, Gautam A, Henderson J, Francis JM. Monoclonal IgG4/2? Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation. Kidney Med. 2019 May-Jun; 1(3):139-143.View Related Profiles. PMID: 32734194
     
  8. Priyamvada Singh, Hui Chen, Craig E. Gordon, Sandeep Ghai, J. Mark Sloan, Karen Quillen, Sara Moradi, Vipul Chitalia, Amitabh Gautam, Joel Henderson, and Jean M. Francis. . Kidney Medicine. Monoclonal IgG4/2? Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation,. Elsevier. 2019; 1(3):139-143.
  9. Kannan S, Morgan LA, Liang B, Cheung MG, Lin CQ, Mun D, Nader RG, Belghasem ME, Henderson JM, Francis JM, Chitalia VC, Kolachalama VB. Segmentation of Glomeruli Within Trichrome Images Using Deep Learning. Kidney Int Rep. 2019 Jul; 4(7):955-962.View Related Profiles. PMID: 31317118
     
  10. Arinze NV, Gregory A, Francis JM, Farber A, Chitalia VC. Unique aspects of peripheral artery disease in patients with chronic kidney disease. Vasc Med. 2019 06; 24(3):251-260.View Related Profiles. PMID: 30823859
     
Showing 10 of 49 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 49 publications over 15 distinct years, with a maximum of 9 publications in 2019

YearPublications
20041
20072
20082
20091
20101
20112
20123
20131
20143
20154
20166
20174
20188
20199
20202

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Education Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Francis's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department